|Description:||1. Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, may potentially be used in osteogenesis imperfecta (OI) type I pharmacotherapy in patients with normal GAG content. |
2. Apigenin 7-O-methylglucuronide which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.
|Source:||The herbs of Thymus serpyllum L.|
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.172 mL||10.8601 mL||21.7202 mL||43.4405 mL||54.3006 mL|
|5 mM||0.4344 mL||2.172 mL||4.344 mL||8.6881 mL||10.8601 mL|
|10 mM||0.2172 mL||1.086 mL||2.172 mL||4.344 mL||5.4301 mL|
|50 mM||0.0434 mL||0.2172 mL||0.4344 mL||0.8688 mL||1.086 mL|
|100 mM||0.0217 mL||0.1086 mL||0.2172 mL||0.4344 mL||0.543 mL|
Mol Med Rep. 2010 May-Jun;3(3):537-41.
|Differential effect of flavonoids on glycosaminoglycan content and distribution in skin fibroblasts of patients with type I osteogenesis imperfecta.[Pubmed: 21472276]|
|We recently reported that, in osteogenesis imperfecta (OI) type I with diminished type I collagen biosynthesis, flavonoids such as apigenin 7-O-glucuronide, Apigenin 7-O-methylglucuronide and pectolinarin normalized the level of collagen type I without affecting total protein synthesis. Apigenin 7-O-methylglucuronide did not affect GAG level or secretion, and thus may potentially be used in OI type I pharmacotherapy in patients with normal GAG content. However, in patients with increased concentrations of GAG, pectolinarin, which decreases GAG content by approximately 40%, may be more beneficial.|
Int J Mol Med. 2007 Dec;20(6):889-95.
|Stimulation of collagen biosynthesis by flavonoid glycosides in skin fibroblasts of osteogenesis imperfecta type I and the potential mechanism of their action.[Pubmed: 17982699]|
|Secretion of collagen into media was not affected by apigenin 7-O-glucuronide and was slightly increased in cells treated with Apigenin 7-O-methylglucuronide and pectolinarin. Stimulation of collagen synthesis and prolidase activity by apigenin 7-O-glucuronide was accompanied by an increase in IGF-I receptor expression. In contrast, the compounds Apigenin 7-O-methylglucuronide and pectolinarin which normalized collagen synthesis in OI cells may exert their effects through beta1-integrin-mediated signaling.|